• FirefoxInstall the new Firefox »
  •  Dow Down1.54% Nasdaq Down1.11%

    bluebird bio, Inc. (BLUE)

    113.14 Up 0.91(0.81%) 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    bluebird bio, Inc.
    150 Second Street
    Cambridge, MA 02141
    United States - Map
    Phone: 339-499-9300
    Website: http://www.bluebirdbio.com

    Index Membership:N/A
    Full Time Employees:143

    Business Summary 

    bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company also develops various CAR T cell products for liquid and solid tumor cancers. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on bluebird bio, Inc.

    Corporate Governance 
    bluebird bio, Inc.’s ISS Governance QuickScore as of Mar 1, 2015 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Nick Leschly , 42
    Chief Exec. Officer, Pres and Director
    Mr. Jeffrey T. Walsh MBA, 49
    Chief Operating Officer
    Dr. Mitchell H. Finer Ph.D., 56
    Chief Scientific Officer
    Mr. Ronald C. Dorazio M.D.,
    Co-Founder, VP of Corp. Devel. and Strategic Advisor
    Mr. Fred F. Nazem , 72
    Managing Gen. Partner
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders